![Page 1: Unlocking Growth Opportunities in CNS Diseases€¦ · controlled opioid delivery platform y Strategic planning for a pain management device franchise y Commercialization strategy](https://reader036.vdocuments.net/reader036/viewer/2022071019/5fd2c733a1ada1020a500f11/html5/thumbnails/1.jpg)
Founded in 1992, Health Advances is a leading healthcare strategy firm advising
clients in the biopharma, diagnostic, device, and healthcare services sectors, as
well as investors and non-profit organizations. Healthcare executives rely on
our professionals to help them make confident decisions involving the greatest
challenges in the commercialization of medical technologies and services
throughout the world.
www.healthadvances.com
UnlockingGrowth
Opportunities inCNS Diseases
Core Competencies
y New Product Commercialization
y Product Forecasting
y Lifecycle Management Strategy
y Clinical Development Planning
y Portfolio Prioritization and Planning
y Franchise Strategy
y Corporate Strategy
y Pricing and Reimbursement
y Pharmacoeconomics
y Licensing and Acquisition
Identification
y Valuation and Due Diligence
Contact: [email protected]
BostonSan FranciscoWashington DCZurich
781-647-3435
www.healthadvances.com
![Page 2: Unlocking Growth Opportunities in CNS Diseases€¦ · controlled opioid delivery platform y Strategic planning for a pain management device franchise y Commercialization strategy](https://reader036.vdocuments.net/reader036/viewer/2022071019/5fd2c733a1ada1020a500f11/html5/thumbnails/2.jpg)
Experience. It’s What Sets Us Apart.
Operating at the intersection of science, technology, and business strategy, Health Advances provides clients with innovative solutions based
on deep industry insight, analytical rigor, and an objective perspective. Example projects include:
Neurodegenerative Diseases
y Licensing strategy for a companyentering Alzheimer’s and Parkinson’smarkets
y Valuation models for multiple novel product concepts inParkinson’s disease
y Market assessment acrossneurodegenerative diseases to guide market entry
y Clinical trial strategy for Alzheimer’simaging agent
y Commercialization strategy andlaunch plan for respiratory supportdevice in ALS
y Development of a road map to expanda disease foundation’s relationshipwith commercial partners
y Strategy for advancing multi-disciplinary Parkinson’s care at a network of medical centers
Pain and Migraine
y Clinical, scientific, and competitiveanalysis of ion channel modulatorsfor use in chronic pain
y Development and co-positioningstrategy for neuropathic painfranchise
y Clinical development and market adoption strategy for a new pain product
y Acquisition diligence of anti-abuseformulation for a novel opioid
y Commercial assessment of acontrolled opioid delivery platform
y Strategic planning for a painmanagement device franchise
y Commercialization strategy forinhaled acute migraine therapy
Multiple Sclerosis
y Identification and prioritization of strategic initiatives for globalneuro-immunology franchise
y Market assessment of RNAi-basedtechnology for immune indications
y Elucidation of neurologist andpatient unmet needs through clinicvisits and on-site interviews
y Development costs and revenueprojections for prognostic andpredictive biomarkers
y US and EU commercializationstrategy for biosimilar interferon
y Launch plan and post-marketing trialdesign for a new injectable therapy
y Portfolio prioritization for an MRIimaging company
Psychiatric Illnesses
y Impact of efficacy and side effects onrevenue projections for generalizedanxiety disorder drug
y Transaction diligence for the acquisition of an antidepressantfranchise
y Revenue implications of increasing price in a highly competitive therapy class
y Strategy to increase CNS exposurethrough licensing and/or acquisition
y Forecast model utilizing detailedtreatment algorithms in depression and related conditions
y Prioritization of indications for a novel,sustained-release drug formulation
y Evaluation of trends in sales andmarketing costs
www.healthadvances.com